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Background
ST2, a member of the interleukin-1 receptor family, has
been shown to be independently associated with myo-
cardial strain and adverse cardiac events in patients with
both ST-elevation and non-ST elevation myocardial
infarction (MI). We sought to determine whether high-
dose omega-3 fatty acid therapy (O-3FA) would reduce
serum levels of ST2 following acute MI and whether
ST2 levels correlated directly with measures of diffuse
myocardial fibrosis within non-infarcted myocardium.
Methods
We evaluated 358 patients who were enrolled in a ran-
domized, double-blinded, placebo-controlled trial of
high-dose O-3FA therapy post acute MI. All patients
underwent 3T CMR (Tim Trio/Verio, Siemens, Germany)
and evaluation of serum biomarkers at enrollment and
after 6-months of randomized study therapy. Patients
were followed for adverse cardiac events by study physi-
cians at 6-month intervals thereafter.
Results
Patients who received O-3FA treatment were more
likely to have a history of coronary bypass surgery than
placebo patients (p = 0.02), otherwise there were no
baseline differences between treatment arms. ST2 levels
were significantly reduced by O-3FA therapy as com-
pared with placebo (Figure 1). By intention-to-treat
analysis, O-3FA treatment was associated with a -7.9%
reduction of ST2 (P = 0.03), and in adjusted analysis for
covariates by -8.0% (P = 0.03). Amongst O-3FA treated
patients, reduction of ST2 demonstrated a strong corre-
lation with reduction of extracellular volume fraction
within non-infarcted myocardium (r = 0.65, P < 0.0001,
Figure 2). Baseline ST2 levels were the strongest unad-
justed predictor (HR 5.2, 95% confidence interval
2.3-11.7, p < 0.0001) for all-cause mortality and conges-
tive heart failure after a median of 2.3 years of follow-up.
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Figure 1 Percent Change of Serum Biomarker ST2 Levels Post
Treatment. Percent change from baseline to post treatment (6
months) of ST2 levels for the high-dose omega-3 fatty acid treated
group and placebo arm. P values are for comparisons of percent
change in ST2 levels between the randomized treatment arms.
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Conclusions
Serum ST2 level following acute MI is a strong prognos-
tic marker of post-MI death and congestive heart failure.
O-3FA treatment reduced ST2 levels, which were
strongly correlated with reduction of the extracellular
volume fraction within non-infarcted myocardium. ST2
may serve as a non-invasive serum biomarker of myo-
cardial fibrosis, as well an independent predictor of
adverse cardiac events following acute MI.
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Figure 2 Scatter Plot of Percent Change in Serum Biomarker ST2 versus Percent Change of Remote Myocardial Fibrosis Post
Treatment. Percent change from baseline to post treatment of the serum biomarker ST2 correlated against percent change in remote
myocardial fibrosis by cardiac magnetic resonance imaging following 6 months of treatment with high-dose omega-3 fatty acids. P value is for
Pearson correlation coefficient shown in figure.
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